Luye Pharma (02186) Announces RMB285 Million Capital Injection in Nanjing Luye, Triggering Discloseable and Connected Transaction

Bulletin Express01-27

Luye Pharma Group Ltd. (02186) announced that on 26 January 2026, Shenzhen Luye, NJ Xinshi, Nanjing Xinan, Ningbo Cinda, and Nanjing Luye entered into agreements for a capital injection totaling RMB285 million by Nanjing Xinan and Ningbo Cinda. Upon completion, Nanjing Luye’s shareholding structure will change to: 70.01% held by Shenzhen Luye, 23.34% by NJ Xinshi, 4.32% by Nanjing Xinan, and 2.33% by Ningbo Cinda.

According to the announcement, the transaction constitutes a deemed disposal under Rule 14.29 of the Listing Rules and also involves put options and call options over Nanjing Luye equity interests. The put options granted to the new investors are classified as discloseable transactions under Chapter 14, while the call options do not constitute notifiable transactions at this stage. As the parties involved are connected persons at the subsidiary level, the transaction is recognized as a connected transaction, subject to announcement requirements but exempt from circular and shareholder approval under Rule 14A.101. The capital will be used to repay existing indebtedness or operating liabilities, with Nanjing Luye remaining a subsidiary of Luye Pharma Group after the injection. The company highlights that this arrangement strengthens Nanjing Luye’s capital structure and provides additional institutional capital support for its oncology-focused operations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140354691?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 07:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140354691","market":"hk","top_or_hot":-1,"title":"Luye Pharma (02186) Announces RMB285 Million Capital Injection in Nanjing Luye, Triggering Discloseable and Connected Transaction","media":"Bulletin Express","content":"<p>Luye Pharma Group Ltd. (02186) announced that on 26 January 2026, Shenzhen Luye, NJ Xinshi, Nanjing Xinan, Ningbo Cinda, and Nanjing Luye entered into agreements for a capital injection totaling RMB285 million by Nanjing Xinan and Ningbo Cinda. Upon completion, Nanjing Luye’s shareholding structure will change to: 70.01% held by Shenzhen Luye, 23.34% by NJ Xinshi, 4.32% by Nanjing Xinan, and 2.33% by Ningbo Cinda.</p>\n<p>According to the announcement, the transaction constitutes a deemed disposal under Rule 14.29 of the Listing Rules and also involves put options and call options over Nanjing Luye equity interests. The put options granted to the new investors are classified as discloseable transactions under Chapter 14, while the call options do not constitute notifiable transactions at this stage. As the parties involved are connected persons at the subsidiary level, the transaction is recognized as a connected transaction, subject to announcement requirements but exempt from circular and shareholder approval under Rule 14A.101. The capital will be used to repay existing indebtedness or operating liabilities, with Nanjing Luye remaining a subsidiary of Luye Pharma Group after the injection. The company highlights that this arrangement strengthens Nanjing Luye’s capital structure and provides additional institutional capital support for its oncology-focused operations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Luye Pharma (02186) Announces RMB285 Million Capital Injection in Nanjing Luye, Triggering Discloseable and Connected Transaction</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLuye Pharma (02186) Announces RMB285 Million Capital Injection in Nanjing Luye, Triggering Discloseable and Connected Transaction\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-01-27 07:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Luye Pharma Group Ltd. (02186) announced that on 26 January 2026, Shenzhen Luye, NJ Xinshi, Nanjing Xinan, Ningbo Cinda, and Nanjing Luye entered into agreements for a capital injection totaling RMB285 million by Nanjing Xinan and Ningbo Cinda. Upon completion, Nanjing Luye’s shareholding structure will change to: 70.01% held by Shenzhen Luye, 23.34% by NJ Xinshi, 4.32% by Nanjing Xinan, and 2.33% by Ningbo Cinda.</p>\n<p>According to the announcement, the transaction constitutes a deemed disposal under Rule 14.29 of the Listing Rules and also involves put options and call options over Nanjing Luye equity interests. The put options granted to the new investors are classified as discloseable transactions under Chapter 14, while the call options do not constitute notifiable transactions at this stage. As the parties involved are connected persons at the subsidiary level, the transaction is recognized as a connected transaction, subject to announcement requirements but exempt from circular and shareholder approval under Rule 14A.101. The capital will be used to repay existing indebtedness or operating liabilities, with Nanjing Luye remaining a subsidiary of Luye Pharma Group after the injection. The company highlights that this arrangement strengthens Nanjing Luye’s capital structure and provides additional institutional capital support for its oncology-focused operations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02186","symbol_name":"绿叶制药","start_time":0,"source_url":"","article_id":"1140354691","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140354691","pubTimestamp":1769468649,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Luye Pharma Group Ltd. (02186) announced that on 26 January 2026, Shenzhen Luye, NJ Xinshi, Nanjing Xinan, Ningbo Cinda, and Nanjing Luye entered into agreements for a capital injection totaling...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02186":"绿叶制药"},"translate_title":"绿叶制药(02186)宣布向南京绿叶注资人民币2.85亿元触发须予披露及关连交易","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02186":1},"content_text":"Luye Pharma Group Ltd. (02186) announced that on 26 January 2026, Shenzhen Luye, NJ Xinshi, Nanjing Xinan, Ningbo Cinda, and Nanjing Luye entered into agreements for a capital injection totaling RMB285 million by Nanjing Xinan and Ningbo Cinda. Upon completion, Nanjing Luye’s shareholding structure will change to: 70.01% held by Shenzhen Luye, 23.34% by NJ Xinshi, 4.32% by Nanjing Xinan, and 2.33% by Ningbo Cinda.\nAccording to the announcement, the transaction constitutes a deemed disposal under Rule 14.29 of the Listing Rules and also involves put options and call options over Nanjing Luye equity interests. The put options granted to the new investors are classified as discloseable transactions under Chapter 14, while the call options do not constitute notifiable transactions at this stage. As the parties involved are connected persons at the subsidiary level, the transaction is recognized as a connected transaction, subject to announcement requirements but exempt from circular and shareholder approval under Rule 14A.101. The capital will be used to repay existing indebtedness or operating liabilities, with Nanjing Luye remaining a subsidiary of Luye Pharma Group after the injection. The company highlights that this arrangement strengthens Nanjing Luye’s capital structure and provides additional institutional capital support for its oncology-focused operations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140354691","isCrawlerRequest":true}